Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks angiotensin receptor. “Guidelines for the Diagnosis and Treatment of Heart Failure in China 2018” made a class Ⅰ recommendation for sacubitril/valsartan that surpassed European and American guidelines. 2021 US Food And Drug Administration approves sacubitril/valsartan for the treatment of heart failure patients with normal ejection fraction. Numerous studies have shown beneficial effects of sacubitril/valsartan in patients with heart failure, myocardial infarction, arrhythmia, hypertension, chronic kidney disease and diabetes. This article reviews the application progress of sacubitril/valsartan in the treatment of cardiovascular disease and related diseases.